Agile Therapeutics Cash Flow - Quarterly (NASDAQ:AGRX)

Add to My Stocks
$0.34 $0.03 (8.11%) AGRX stock closing price Sep 19, 2018 (Closing)

The Agile Therapeutics cash flow statement is one of the important reports considered by investors doing a fundamental analysis of the company. In simple terms, the cash flow statement measures the cash that has come into the company, and the cash that has gone out during a given period, while the other statements, the income statement and balance sheet, give details about Agile Therapeutics profits and Agile Therapeutics debt. Agile Therapeutics stock analysis shows negative net income cash flow of $-12.18M till 2018 Q2. This statement is important because profits alone cannot pay employees, or bills. Cash is required. Agile Therapeutics saw a outflow of $-0.32M from investing activities till 2018 Q2.

View and download details of Agile Therapeutics cash flows for latest & last 40 quarters
show more
View Previous Quarters
View Next Quarters
Fiscal year is Jan - Dec2018 Q22018 Q12017 Q42017 Q32017 Q22017 Q12016 Q42016 Q32016 Q22016 Q1
Net Income Cash Flow
Depreciation Depletion Amortization Cash-Flow----------
Net Increase (Decrease) in Assets Liabilities-0.08M-0.14M-0.45M-1.01M-1.28M-0.05M--0.11M
Cash From (used in) Discontinued Operations----------
Other Adjustments Net2.34M1.25M4.17M3.16M2.01M-4.13M3.19M1.88M-
Net Cash from (used by) Operating Activities
Increase (Decrease) in Prop Plant And Equipment-0.32M-0.27M-1.31M-0.77M-0.45M-0.01M-0.03M-0.02M-0.02M-
Acquisition Disposition of Subsidiaires----------
Increase (Decrease) in Investments----------
Other Cash Inflow (Outflow) from Investment Activities----------
Net Cash from (used by) Investment Activities
Issuance (Purchase) of Equity Shares--18.68M18.61M--37.86M37.85M37.84M37.84M
Issuance (Repayment) of Debt Securities-3.26M-1.61M-5.61M-4.03M-2.49M-0.99M----
Increase (Decrease) in Bank & Other Borrowings----------
Payment of Dividends & Other Cash Distributions----------
Other Cash from (used by) Financing Activities-------0.17M-0.17M--
Net Cash from (used by) Financing Activities
Effect of Exchange Rate Changes on Cash----------
Net Change in Cash & Cash Equivalents
Cash & Equivalents at Beginning of Year35.95M48.75M34.39M40.18M2.11M20.01M9.56M---
Cash & Equivalents at Year End22.47M28.34M35.95M43.8M33.93M41.74M48.75M51.67M59.22M65.49M
All figures in USD. M: Millions of USD, B: Billions of USD.
View Previous Quarters
View Next Quarters

The statement of cash flows comprises of cash flow from financing, cash flow from operations and cash flow from investing activities. All the three can have an impact on the stock price. The Agile Therapeutics stock price history and Agile Therapeutics stock comparison chart inevitably reflect its cash flow situation.

  • Agile Therapeutics had a Net Change in Cash and Cash Equivalents of $-13.49M in the latest quarter 2018 Q2. If a firm is able to grow its cash, it is considered to be a positive signal and could lead to a jump in the Agile Therapeutics stock price, albeit too much cash on hand can imply the company has no or limited avenues for growth in which to invest this cash.
  • Cash Flow from operating activities: Operating activities include the core business activities. This line item refers to the cash generated from the same and stood at a negative value of $-9.91M for AGRX.
  • Cash Flow from investment activities: Agile Therapeutics used $-0.32M cash due to investment activities. It includes the use of cash outside of normal day to day activities like buying fixed assets, plant and machinery etc.
  • Cash Flow from financing activities: The cash inflow/outflow from financing activities was $-3.26M for Agile Therapeutics. The money accounted for under this head comes from external sources which includes lenders, investors and shareholders. Positive cash flow is generated when the company gets cash because of issuance of stocks or bonds. Similarly negative cash flow is generated when shares are repurchased, dividend payments are made, and loans or interest on loans are paid back.

Key Financial Ratios For Agile Therapeutics Cash Flow

Quarterly Cash Flow Statements For Agile Therapeutics Inc Peers

Acasti Pharma cash flow, Juniper Pharma cash flow, Merck cash flow, Pfizer cash flow, Versartis cash flow